Target
$878.66 → $878.34
Current stock research snapshot · 7/31/26 26 days old
REGNRegeneron
Investment conviction●●○○○2 of 5 · current snapshot
Research target$878.34Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/31/26
Market cap$72.91BSnapshot value · 7/31/26
Research history
See all REGN changes ↗What changed
Healthspan taxonomy seed — see taxonomy_path
Regeneron Q2 2026 earnings; Eylea HD (aflibercept) market share; Dupixent revenue growth; antibody platform pipeline; Odronextamab approval timeline
Thesis breaks if Dupixent/EYLEA HD two-franchise concentration (80.6% of revenue) faces competitive setback or accelerated biosimilar, EYLEA 2mg managed decline (-45%) accelerates, Bayer ex-US -33% worsens, or 38% R&D intensity fails to yield pipeline wins. (vault 2026-08)
Neutral — No substantive investor/analyst discussion found (only futures listings). [X search Aug 2026]
Snapshot · 7/31/26🟡 Mixed · ins-$1.2M · 13F 13+/12-×0.5 · short↑0.31
Snapshot · 7/31/26